Phase 3 HIV and AIDS Trial, Recruiting NCT06550804 Sponsor: University of Illinois at Chicago Condition: HIV and AIDS
Back to Hiv Aids

Phase 3 HIV and AIDS Trial, Recruiting

NCT06550804
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the main participants (African American men who have sex with men):

  • You are an African American man who has sex with men, are over 18 years old, and have HIV
  • You own a working cell phone
  • You have been taking HIV medication (antiretroviral therapy) for at least 6 months
  • You have a case manager who is willing to take part in the study
  • You have been having trouble taking your HIV medication consistently — this means either your virus levels were detectable in the last 6 months, you reported missing more than 10% of your doses, or your doctor referred you due to concerns about missed medication

For support persons (a friend, family member, or other trusted person):

  • You have a close, meaningful relationship with the main participant
  • You are over 18 years old
  • You own a working cell phone
  • You are willing to provide support to the participant

For case managers:

  • You have worked with HIV-positive clients for at least 6 months before joining the study
  • You own a working cell phone

Who may not be able to join:

  • Anyone who does not meet the requirements listed above
  • Anyone who does not agree to give informed consent for interactions with the research team, data collection, and access to their medical records
  • Anyone who does not agree to allow the research team to access their virus level (viral load) test results from the 12 months before and after the study begins

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark Dworkin, MD, University of Illinois at Chicago

Phone: 3124130348

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Illinois at Chicago
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 February 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Viral load suppression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov